Accure receives CE Mark Approval for 1726nm laser platform to treat acne

67

Accure Acne, Inc., a pioneer in innovative energy-based solutions for the acne market, announced it has been granted the European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands, the fundamental source of sebum production and the key to a durable solution for acne.

Founded in 2015, Accure is wholly focused on the elimination of acne through innovative and disruptive non-systemic solutions. Acne represents one of the most common skin conditions in the world, estimated to affect 9.4% of the global population.2 Recent studies have also shown a significant link between acne and depression, as well as anxiety.

“This achievement represents the culmination from two decades of clinical research led by The Wellman Center for Photomedicine at Massachusetts General Hospital,” noted Christopher Carlton, Chairman, Chief Executive Officer and co-Founder of Accure. “This milestone brings an impactful solution to millions of acne sufferers in Europe.”

Accure’s clinical and technical development teams represent an unmatched collaboration of engineering acumen and clinical expertise, led by Prof. Rox Anderson, M.D., co-Founder of Accure. Dr. Anderson is an influential medical scientist and inventor dedicated to the field of light and energy-based devices used in dermatology, medical aesthetics, and various specialties.

Preliminary clinical data from Accure’s on-going IRB-approved Face Trial demonstrates an over 80% inflammatory lesion reduction at three months after treatment.4 Accure has compiled hundreds of in vivo human skin histology samples depicting a significant effect on sebaceous glands. Dr. Emil Tanghetti, a principal investigator of the Accure Laser, stated, “I am impressed with Accure’s safety-first, data-driven approach. The clinical results thus far are exciting, and the uniqueness of the proprietary temperature and operator feedback control systems makes this much more than just a new laser wavelength. I look forward to on-going advances with this platform.”

Accure is proud to partner with Quanta System, S.p.A (El.En. Group), based in Milan, Italy. Quanta has contributed substantial resources and expertise to the development of the Accure Laser and will be the exclusive manufacturing partner of Accure as commercial activities accelerate. The laser platform has been designed with highly unique and innovative technology, resulting in over fourteen granted, pending, and provisional patents issued to Accure through exclusive global licenses. “Quanta is proud to support such an innovative and important device for the field of dermatology”, added Paolo Salvadeo, General Manager of El.En. “We look forward to the impact of this technology in Europe and around the world.”